FGFR3 and urothelial carcinoma: Activating mutations in FGFR3 are found at high frequency in low-grade non-invasive (stage Ta) urothelial carcinoma (UC) [18] and several studies have highlighted activated FGFR3 as a potential therapeutic target in this subgroup [19], [20], [21].